Medicines in Development
Tasly U.S., “Dedicated to a Healthier World,” has a range of alternative medicines in development that are intended to address unmet health needs and offer disease prevention options in a number of key medical areas, including cardiovascular health, liver health, oncology, immunology and stem cell research.
|PRE-CLINICAL||PHASE I||PHASE II||PHASE III a||PHASE III b|
|Cardiovascular||T89||Herbal||Chronic stable angina||Phase III trial completed|
|Cardiovascular||T89||Herbal||Chronic stable angina||Phase III ORESA study
|Cardiovascular||T89||Herbal||Acute mountain sickness (AMS)||Phase II T89-30-AMS trial completed; Phase III clinical trial will be initiated in Q2 of 2021
|Oncology||TSL1502||Small Molecule||Ovarian cancer, prostate cancer, breast cancer, stomach cancer, and lung cancer, pancreatic cancer||IND granted by FDA in April 2019; Phase I study ongoing (in China)|
|Liver||HEPA44||Polypeptide||Hepatitis B||Applying for an IND to conduct clinical trial in the U.S.|
|Stem cell||UMSC01||Stem Cell||Acute myocardial infarction and ischemic stroke||A Phase I open label clinical trial is currently being performed with an estimated completion in 2021.
|Immunology||TA06||Biological||An innovative technology of enzymatic digestion, or sample deglycosylation, which significantly boosts anti-PD-L1 antibody binding affinity and signal intensity causing a more precise PD-L1 quantification and prediction of clinical outcome.|